PMID- 26546891
OWN - NLM
STAT- MEDLINE
DCOM- 20160512
LR  - 20151108
IS  - 1735-1502 (Print)
IS  - 1735-1502 (Linking)
VI  - 14
IP  - 3
DP  - 2015 Jun
TI  - Human Leukocyte Antigens Influence the Antibody Response to Hepatitis B Vaccine.
PG  - 233-45
AB  - Hepatitis B virus (HBV) infection and its sequelae such as cirrhosis and 
      hepatocellular carcinoma has remained a serious public health problem throughout 
      the world. The WHO strategy for effective control of HBV infection and its 
      complications is mass vaccination of neonates and children within the framework 
      of Expanded Programme on Immunization (EPI). Vaccination with hepatitis B surface 
      antigen (HBsAg) induces protective antibody response (anti-HBs >/= 10 IU/L) in 
      90-99% of vaccinees. The lack of response to HBsAg has been attributed to a 
      variety of immunological mechanisms, including defect in antigen presentation, 
      defect in HBsAg-specific T and/or B cell repertoires, T-cell suppression, 
      increase in the regulatory T cell count, lack of necessary help of T-cells for 
      production of anti-HBs by B cells, defect in Th1 and/or Th2 cytokine production 
      and selective killing of HBsAg-specific B-cells by human leukocyte antigen 
      (HLA)-restricted cytotoxic T lymphocytes. The HLA complex plays an important role 
      in many of these immunological processes. A variety of HLA class I, II, and III 
      alleles and antigens have been reported to be associated with antibody response 
      to HBsAg vaccination in different ethnic populations. Moreover, some HLA 
      haplotypes were also associated with responsiveness to HBsAg. In this review the 
      association of the HLA specificities with antibody response to hepatitis B (HB) 
      vaccine is discussed.
FAU - Jafarzadeh, Abdollah
AU  - Jafarzadeh A
AD  - Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, 
      Rafsanjan, Iran AND Department of Immunology, School of Medicine, Rafsanjan 
      University of Medical Sciences, Rafsanjan, Iran AND Department of Immunology, 
      School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
FAU - Bagheri-Jamebozorgi, Masoome
AU  - Bagheri-Jamebozorgi M
AD  - Department of Immunology, School of Medicine, Rafsanjan University of Medical 
      Sciences, Rafsanjan, Iran.
FAU - Nemati, Maryam
AU  - Nemati M
AD  - Department of Immunology, School of Medicine, Kerman University of Medical 
      Sciences, Kerman, Iran.
FAU - Golsaz-Shirazi, Forough
AU  - Golsaz-Shirazi F
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Shokri, Fazel
AU  - Shokri F
AD  - Department of Immunology, School of Public Health, Tehran University of Medical 
      Sciences, Tehran, Iran AND Monoclonal Antibody Research Center, Avicenna Research 
      Institute, ACECR, Tehran, Iran.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Iran
TA  - Iran J Allergy Asthma Immunol
JT  - Iranian journal of allergy, asthma, and immunology
JID - 101146178
RN  - 0 (HLA Antigens)
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Vaccines)
SB  - IM
MH  - HLA Antigens/*genetics
MH  - Haplotypes
MH  - Hepatitis B Antibodies/*blood
MH  - Hepatitis B Vaccines/*immunology
MH  - Humans
MH  - Lymphocytes/immunology
OTO - NOTNLM
OT  - Hepatitis B antibodies
OT  - Hepatitis B vaccine
OT  - Human leukocyte antigen
EDAT- 2015/11/08 06:00
MHDA- 2016/05/14 06:00
CRDT- 2015/11/08 06:00
PHST- 2015/10/18 00:00 [accepted]
PHST- 2015/11/08 06:00 [entrez]
PHST- 2015/11/08 06:00 [pubmed]
PHST- 2016/05/14 06:00 [medline]
PST - ppublish
SO  - Iran J Allergy Asthma Immunol. 2015 Jun;14(3):233-45.